Induced pluripotent stem cells for modeling of pediatric neurological disorders

Biotechnology Journal

Volumn 9, Issue 7, 2014, Pages 871-891

  Jang, Jiho ^a   Quan, Zhejiu ^a,b,c,d   Yum, Yunjin J ^a,b,c,d   Song, Hyo Sook ^a,b,c,d   Paek, Seonyeol ^a,b,c,d   Kang, Hoon Chul ^a,b,c,d  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Hallym Institute of Epilepsy Research   (South Korea)

^d Stem Cell Research Center   (South Korea)

Author keywords

Cell based therapy; Disease modeling; Drug screening; Induced pluripotent stem cells; Pediatric neurological disorders

Indexed keywords

DISEASE CONTROL; GENE TRANSFER; NEURODEGENERATIVE DISEASES; PEDIATRICS; STEM CELLS;

CELL-BASED THERAPY; DISEASE MODELING; DRUG SCREENING; INDUCED PLURIPOTENT STEM CELLS; NEUROLOGICAL DISORDERS;

NEUROLOGY;

ADENOVIRUS VECTOR; EPISOMAL VECTOR; FRAGILE X MENTAL RETARDATION PROTEIN; FRATAXIN; GENE THERAPY AGENT; LENTIVIRUS VECTOR; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; MICRORNA; MINICIRCLE DNA; PLASMID VECTOR; PROTEIN; RETROVIRUS VECTOR; SODIUM CHANNEL NAV1.1; SURVIVAL MOTOR NEURON PROTEIN 1; UNCLASSIFIED DRUG;

ABCD1 GENE; ADRENOLEUKODYSTROPHY; BENIGN CHILDHOOD EPILEPSY; CHILD; CHILDHOOD DISEASE; CHROMOSOME 21; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DOWN SYNDROME; EPISOME; FRAGILE X MENTAL RETARDATION GENE; FRAGILE X SYNDROME; FRATAXIN GENE; FRIEDREICH ATAXIA; GENE; GENE DELIVERY SYSTEM; GENE MUTATION; GENE TARGETING; GENE VECTOR; HAPPY PUPPET SYNDROME; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; METHYL CPG BINDING GENE 2; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; NUCLEAR REPROGRAMMING; PLURIPOTENT STEM CELL; PRADER WILLI SYNDROME; PRIORITY JOURNAL; RETT SYNDROME; REVIEW; SENDAI VIRUS; SODIUM CHANNEL NAV1.1 GENE; SPINAL MUSCULAR ATROPHY; STEM CELL TRANSPLANTATION; SURVIVAL MOTOR NEURON GENE 1; TRANSPOSON; X CHROMOSOME LINKED DISORDER; ANIMAL; BIOLOGICAL MODEL; CHILD DEVELOPMENT; CYTOLOGY; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES; PHYSIOLOGY;

ANIMALS; CHILD; CHILD DEVELOPMENT; DISEASE MODELS, ANIMAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, NEUROLOGICAL; NERVOUS SYSTEM DISEASES; NEURODEGENERATIVE DISEASES;

EID: 84903818907     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400010     Document Type: Review

References (94)

1. Marchetto, M. C., Brennand, K. J., Boyer, L. F., Gage, F. H., Induced pluripotent stem cells (IPSCs) and neurological disease modeling: Progress and promises. Hum. Mol. Genet. 2011, 20, R109-115.
2. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M. et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131, 861-872.
3. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J. et al., Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318, 1917-1920.
4. Kim, K., Doi, A., Wen, B., Ng, K. et al., Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467, 285-290
5. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., Yamanaka, S., Generation of mouse induced pluripotent stem cells without viral vectors. Science 2008, 322, 949-953.
6. Woltjen, K., Michael, I. P., Mohseni, P., Desai, R. et al., Piggybac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature 2009, 458, 766-770.
7. Jia, F., Wilson, K. D., Sun, N., Gupta, D. M. et al., A nonviral minicircle vector for deriving human ips cells. Nat. Meth. 2010, 7, 197-199.
8. Kim, D., Kim, C. H., Moon, J. I., Chung, Y. G. et al., Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009, 4, 472-476.
9. Ban, H., Nishishita, N., Fusaki, N., Tabata, T. et al., Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive sendai virus vectors. Proc. Nat. Acad. Sci. USA 2011, 108, 14234-14239.
10. Okita, K., Matsumura, Y., Sato, Y., Okada, A. et al., A more efficient method to generate integration-free human iPS cells. Nat. Meth. 2011, 8, 409-412.
11. Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H. et al., Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010, 7, 618-630.
12. Hou, P., Li, Y., Zhang, X., Liu, C. et al., Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013, 341, 651-654.
13. Mikkelsen, T. S., Hanna, J., Zhang, X., Ku, M. et al., Dissecting direct reprogramming through integrative genomic analysis. Nature 2008, 454, 49-55.
14. Hanna, J., Cheng, A. W., Saha, K., Kim, J. et al., Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc. Nat. Acad. Sci. USA 2010, 107, 9222-9227.
15. Huangfu, D., Osafune, K., Maehr, R., Guo, W. et al., Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat. Biotechnol. 2008, 26, 1269-1275.
16. Esteban, M. A., Wang, T., Qin, B., Yang, J. et al., Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell 2010, 6, 71-79.
17. Mali, P., Chou, B. K., Yen, J., Ye, Z. et al., Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 2010, 28, 713-720.
18. Moriguchi, H., Chung, R. T., Mihara, M., Sato, C., Generation of human induced pluripotent stem cells from liver progenitor cells by only small molecules. Hepatology 2010, 52, 1169; author reply 1169-1170.
19. Chen, T., Shen, L., Yu, J., Wan, H. et al., Rapamycin and other longevity-promoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011, 10, 908-911.
20. Wang, Q., Xu, X., Li, J., Liu, J. et al., Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res. 2011, 21, 1424-1435.
21. Zhao, Y., Yin, X., Qin, H., Zhu, F. et al., Two supporting factors greatly improve the efficiency of human ipsc generation. Cell Stem Cell 2008, 3, 475-479.
22. Mathew, R., Jia, W., Sharma, A., Zhao, Y. et al., Robust activation of the human but not mouse telomerase gene during the induction of pluripotency. FASEB J. 2010, 24, 2702-2715.
23. Buganim, Y., Faddah, D. A., Cheng, A. W., Itskovich, E. et al., Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 2012, 150, 1209-1222.
24. Rais, Y., Zviran, A., Geula, S., Gafni, O. et al., Deterministic direct reprogramming of somatic cells to pluripotency. Nature 2013, 502, 65-70.
25. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A. et al., Embryonic stem cell lines derived from human blastocysts. Science 1998, 282, 1145-1147.
26. Boch, J., Scholze, H., Schornack, S., Landgraf, A. et al., Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326, 1509-1512.
27. Sanjana, N. E., Cong, L., Zhou, Y., Cunniff, M. M. et al., A transcription activator-like effector toolbox for genome engineering. Nat. Protoc. 2012, 7, 171-192.
28. Mali, P., Yang, L., Esvelt, K. M., Aach, J. et al., RNA-guided human genome engineering via cas9. Science 2013, 339, 823-826.
29. Merkle, F. T., Eggan, K., Modeling human disease with pluripotent stem cells: From genome association to function. Cell Stem Cell 2013, 12, 656-668.
30. Hanna, J., Wernig, M., Markoulaki, S., Sun, C. W. et al., Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318, 1920-1923.
31. Soldner, F., Laganiere, J., Cheng, A. W., Hockemeyer, D. et al., Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 2011, 146, 318-331.
32. Schwank, G., Koo, B. K., Sasselli, V., Dekkers, J. F. et al., Functional repair of cftr by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013, 13, 653-658.
33. Zhao, T., Zhang, Z. N., Rong, Z., Xu, Y., Immunogenicity of induced pluripotent stem cells. Nature 2011, 474, 212-215.
34. Emborg, M. E., Liu, Y., Xi, J., Zhang, X. et al., Induced pluripotent stem cell-derived neural cells survive and mature in the nonhuman primate brain. Cell Rep. 2013, 3, 646-650.
35. Araki, R., Uda, M., Hoki, Y., Sunayama, M. et al., Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494, 100-104.
36. Takahashi M., Pilot clinical study into iPS cell therapy for eye disease starts in Japan. RIKEN Press Release 2013.
37. Homma, K., Okamoto, S., Mandai, M., Gotoh, N. et al., Developing rods transplanted into the degenerating retina of Crx-knockout mice exhibit neural activity similar to native photoreceptors. Stem Cells 2013, 31, 1149-1159.
38. Kamao, H., Mandai, M., Okamoto, S., Sakai, N. et al., Characterization of human induced pluripotent stem cell-derived retinal pigment epithelium cell sheets aiming for clinical application. Stem Cell Reports 2014, 2, 205-218.
39. Schwartz, S. D., Hubschman, J. P., Heilwell, G., Franco-Cardenas, V. et al., Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012, 379, 713-720.
40. Nicholas, C. R., Chen, J., Tang, Y., Southwell, D. G. et al., Functional maturation of hPSC-derived forebrain interneurons requires an extended timeline and mimics human neural development. Cell Stem Cell 2013, 12, 573-586.
41. Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q. et al., Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 1999, 23, 185-188.
42. Hagberg, B., Aicardi, J., Dias, K., Ramos, O., A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: Report of 35 cases. Ann. Neurol. 1983, 14, 471-479.
43. Cheung, A. Y., Horvath, L. M., Grafodatskaya, D., Pasceri, P. et al., Isolation of MECP2-null Rett syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum. Mol. Genet. 2011, 20, 2103-2115.
44. Kim, K. Y., Hysolli, E., Park, I. H., Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc. Nat. Acad. Sci. USA 2011, 108, 14169-14174.
45. Marchetto, M. C., Carromeu, C., Acab, A., Yu, D. et al., A model for neural development and treatment of rett syndrome using human induced pluripotent stem cells. Cell 2010, 143, 527-539.
46. Singer, T., McConnell, M. J., Marchetto, M. C., Coufal, N. G., Gage, F. H., Line-1 retrotransposons: Mediators of somatic variation in neuronal genomes? Trends Neurosci. 2010, 33, 345-354.
47. Muotri, A. R., Marchetto, M. C., Coufal, N. G., Oefner, R. et al., L1 retrotransposition in neurons is modulated by Mecp2. Nature 2010, 468, 443-446.
48. Evans, P. D., Gilbert, S. L., Mekel-Bobrov, N., Vallender, E. J. et al., Microcephalin, a gene regulating brain size, continues to evolve adaptively in humans. Science 2005, 309, 1717-1720.
49. Amenduni, M., De Filippis, R., Cheung, A. Y., Disciglio, V. et al., iPS cells to model Cdkl5-related disorders. Eur. J. Human. Genet. 2011, 19, 1246-1255.
50. Warren, S. T., Ashley, C. T. Jr., Triplet repeat expansion mutations: The example of fragile x syndrome. Ann. Rev. Neurosci. 1995, 18, 77-99.
51. Garber, K. B., Visootsak, J., Warren, S. T., Fragile x syndrome. Eur. J. Hum. Genet. 2008, 16, 666-672.
52. Eiges, R., Urbach, A., Malcov, M., Frumkin, T. et al., Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos. Cell Stem Cell 2007, 1, 568-577.
53. Urbach, A., Bar-Nur, O., Daley, G. Q., Benvenisty, N., Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 2010, 6, 407-411.
54. Sheridan, S. D., Theriault, K. M., Reis, S. A., Zhou, F. et al., Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile x syndrome. PLoS One 2011, 6, e26203.
55. Antonarakis, S. E., Epstein, C. J., The challenge of down syndrome. Trends Mol. Med. 2006, 12, 473-479.
56. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A., Deutsch, S., Chromosome 21 and down syndrome: From genomics to pathophysiology. Nature Rev. Genet. 2004, 5, 725-738.
57. Shi, Y., Kirwan, P., Smith, J., MacLean, G. et al., A human stem cell model of early alzheimer's disease pathology in down syndrome. Sci. Transl. Med. 2012, 4, 124ra129.
58. Esposito, G., Imitola, J., Lu, J., De Filippis, D. et al., Genomic and functional profiling of human down syndrome neural progenitors implicates s100b and aquaporin 4 in cell injury. Human Mol. Genet. 2008, 17, 440-457.
59. Park, I. H., Arora, N., Huo, H., Maherali, N. et al., Disease-specific induced pluripotent stem cells. Cell 2008, 134, 877-886.
60. Williams, C. A., Driscoll, D. J., Dagli, A. I., Clinical and genetic aspects of angelman syndrome. Genet. Med. 2010, 12, 385-395.
61. Bittel, D. C., Butler, M. G., Prader-willi syndrome: Clinical genetics, cytogenetics and molecular biology. Exp. Rev. Mol. Medi. 2005, 7, 1-20.
62. Chamberlain, S. J., Chen, P. F., Ng, K. Y., Bourgois-Rocha, F. et al., Induced pluripotent stem cell models of the genomic imprinting disorders angelman and prader-willi syndromes. Proc. Nat. Acad. Sci. USA 2010, 107, 17668-17673.
63. Yang, J., Cai, J., Zhang, Y., Wang, X. et al., Induced pluripotent stem cells can be used to model the genomic imprinting disorder Prader-Willi syndrome. J. Biol. Chem. 2010, 285, 40303-40311.
64. Prior, T. W., Perspectives and diagnostic considerations in spinal muscular atrophy. Genet. Med. 2010, 12, 145-152.
65. Lorson, C. L., Rindt, H., Shababi, M., Spinal muscular atrophy: Mechanisms and therapeutic strategies. Hum. Mol. Genet. 2010, 19, R111-118.
66. Chang, T., Zheng, W., Tsark, W., Bates, S. et al., Brief report: Phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. Stem Cells 2011, 29, 2090-2093.
67. Ebert, A. D., Yu, J., Rose, F. F. Jr., Mattis, V. B. et al., Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457, 277-280.
68. Pandolfo, M., Friedreich ataxia. Arch. Neurol. 2008, 65, 1296-1303.
69. Ku, S., Soragni, E., Campau, E., Thomas, E. A. et al., Friedreich's ataxia induced pluripotent stem cells model intergenerational gaattc triplet repeat instability. Cell Stem Cell 2010, 7, 631-637.
70. Liu, J., Verma, P. J., Evans-Galea, M. V., Delatycki, M. B. et al., Generation of induced pluripotent stem cell lines from friedreich ataxia patients. Stem Cell Reviews 2011, 7, 703-713.
71. Moser, H. W., Mahmood, A., Raymond, G. V., X-linked adrenoleukodystrophy. Nat. Rev. Neurolo. Neurology 2007, 3, 140-151.
72. Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P. et al., Putative x-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993, 361, 726-730.
73. Kemp, S., Pujol, A., Waterham, H. R., van Geel, B. M. et al., Abcd1 mutations and the X-linked adrenoleukodystrophy mutation database: Role in diagnosis and clinical correlations. Hum. Mutat. 2001, 18, 499-515.
74. Jang, J., Kang, H. C., Kim, H. S., Kim, J. Y. et al., Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann. Neurol. 2011, 70, 402-409.
75. Singh, I., Pahan, K., Khan, M., Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS Lett. 1998, 426, 342-346.
76. Higurashi, N., Uchida, T., Lossin, C., Misumi, Y. et al., A human dravet syndrome model from patient induced pluripotent stem cells. Mol. Brain 2013, 6, 19.
77. Liu, Y., Lopez-Santiago, L. F., Yuan, Y., Jones, J. M. et al., Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann. Neurol. 2013, 74, 128-139.
78. Jiao, J., Yang, Y., Shi, Y., Chen, J. et al., Modeling dravet syndrome using induced pluripotent stem cells (iPSCs) and directly converted neurons. Hum. Mol. Genet. 2013, 22, 4241-4252.
79. Stafstrom, C. E., Severe epilepsy syndromes of early childhood: The link between genetics and pathophysiology with a focus on scn1a mutations. J. Child Neurol. 2009, 24, 15S-23.
80. Stafstrom, C. E., Persistent sodium current and its role in epilepsy. Epilepsy Curr. 2007, 7, 15-22.
81. Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A. et al., Reduced sodium current in gabaergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nature Neurosci. 2006, 9, 1142-1149.
82. Lowry, W. E., Richter, L., Yachechko, R., Pyle, A. D. et al., Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc. Nat. Acad. Sci. USA 2008, 105, 2883-2888.
83. Moore, J. C., Generation of human-induced pluripotent stem cells by lentiviral transduction. Meth. Mol. Biol. 2013, 997, 35-43.
84. Maherali, N., Ahfeldt, T., Rigamonti, A., Utikal, J. et al., A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008, 3, 340-345.
85. Somers, A., Jean, J. C., Sommer, C. A., Omari, A. et al., Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010, 28, 1728-1740.
86. Stadtfeld, M., Brennand, K., Hochedlinger, K., Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Curr. Biol. 2008, 18, 890-894.
87. Zhou, W., Freed, C.R., Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells 2009, 11, 2667-2674.
88. Si-Tayeb, K., Noto, F. K., Sepac, A., Sedlic, F. et al., Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev. Biol. 2010, 10, 81.
89. Hu, K., Yu, J., Suknuntha, K., Tian, S. et al., Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. Blood 2011, 117, e109-119.
90. Narsinh, K. H., Jia, F., Robbins, R. C., Kay, M. A. et al., Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors. Nature Protoco. 2011, 6, 78-88.
91. Kumano, K., Arai, S., Hosoi, M., Taoka, K. et al., Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood 2012, 119, 6234-6242.
92. Churko, J., Burridge, P., Wu, J., Generation of human ipscs from human peripheral blood mononuclear cells using non-integrative sendai virus in chemically defined conditions, in: Kao, R. L. (Ed.), Cellular cardiomyoplasty, Humana Press 2013, pp. 81-88.
93. Zhou, H., Wu, S., Joo, J.Y., Zhu, S. et al., Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009, 5, 381-384.
94. Miyoshi, N., Ishii, H., Nagano, H., Haraguchi, N. et al., Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011, 8, 633-638.